Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model

Authors

Keywords

Journal

Volume 18, Issue 2, Pages 247-255

Publisher

Wiley

Online

2010-09-16

DOI

10.1111/j.1365-2753.2010.01546.x

References

View 4 related references

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started